Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial by McAuley, Daniel F et al.
Keratinocyte growth factor for the treatment of the acute respiratory
distress syndrome (KARE): a randomised, double-blind, placebo-
controlled phase 2 trial
McAuley, D. F., Cross, LJ. M., Hamid, U., Gardner, E., Elborn, J. S., Cullen, K. M., ... O'Kane, C. M. (2017).
Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised,
double-blind, placebo-controlled phase 2 trial. DOI: 10.1016/S2213-2600(17)30171-6
Published in:
The Lancet Respiratory Medicine
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2017 Elsevier.
This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License
(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the
author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:09. Sep. 2018
Keratinocyte growth factor for the treatment of the acute respiratory
distress syndrome (KARE): a randomised, double-blind, placebo-
controlled phase 2 trial
McAuley, D. F., Cross, L. J. M., Hamid, U., Gardner, E., Elborn, J. S., Cullen, K. M., ... O'Kane, C. M. (2017).
Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised,
double-blind, placebo-controlled phase 2 trial. The Lancet Respiratory Medicine, 5(6), 484-491. DOI:
10.1016/S2213-2600(17)30171-6
Published in:
The Lancet Respiratory Medicine
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:28. Jul. 2017
Time in days
Pr
ob
ab
ilit
y 
of
 S
ur
vi
va
l
0 20 40 60 80
0 %
25 %
50 %
75 %
100 %
No. at risk at interval
29 20 18 17 17KGF
31 30 27 27 26Placebo
   Log−rank: p= 0.006
KGF
Placebo
Survival
Keratinocyte growth factor for the treatment of the acute respiratory
distress syndrome (KARE): a randomised, double-blind, placebo-
controlled phase 2 trial
McAuley, D. F., Cross, L. J. M., Hamid, U., Gardner, E., Elborn, J. S., Cullen, K. M., ... O'Kane, C. M. (2017).
Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised,
double-blind, placebo-controlled phase 2 trial. The Lancet Respiratory Medicine, 5(6), 484-491. DOI:
10.1016/S2213-2600(17)30171-6
Published in:
The Lancet Respiratory Medicine
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:28. Jul. 2017
Time in days
Pr
ob
ab
ilit
y 
of
 u
na
ss
ist
ed
 b
re
at
hi
ng
0 10 20 30 40 50 60
0 %
25 %
50 %
75 %
100 %
No. at risk at interval
15 15 6 4 3 2 1KGF
27 19 4 1 1 1 0Placebo
   Log−rank: p= 0.006
KGF
Placebo
Time to unassisted breathing (survivors only)
Keratinocyte growth factor for the treatment of the acute respiratory
distress syndrome (KARE): a randomised, double-blind, placebo-
controlled phase 2 trial
McAuley, D. F., Cross, L. J. M., Hamid, U., Gardner, E., Elborn, J. S., Cullen, K. M., ... O'Kane, C. M. (2017).
Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised,
double-blind, placebo-controlled phase 2 trial. The Lancet Respiratory Medicine, 5(6), 484-491. DOI:
10.1016/S2213-2600(17)30171-6
Published in:
The Lancet Respiratory Medicine
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:28. Jul. 2017
0
5
10
15
Fr
eq
ue
nc
y
0 100 200 30050 150 250
OI baseline
Oxygenation index Baseline
0
10
20
30
Fr
eq
ue
nc
y
0 50 100 150 200 300250
OI day7
Oxygenation index Day 7
0
5
10
15
20
Fr
eq
ue
nc
y
0 10 20 30 40 50
PF ratio baseline
PaO2/FiO2 ratio Baseline
0
5
10
15
Fr
eq
ue
nc
y
10 20 30 40 500
PF ratio day7
PaO2/FiO2 ratio Day 7
Keratinocyte growth factor for the treatment of the acute respiratory
distress syndrome (KARE): a randomised, double-blind, placebo-
controlled phase 2 trial
McAuley, D. F., Cross, L. J. M., Hamid, U., Gardner, E., Elborn, J. S., Cullen, K. M., ... O'Kane, C. M. (2017).
Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised,
double-blind, placebo-controlled phase 2 trial. The Lancet Respiratory Medicine, 5(6), 484-491. DOI:
10.1016/S2213-2600(17)30171-6
Published in:
The Lancet Respiratory Medicine
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:28. Jul. 2017
Protocol No: 10089DMCA-CS, Version No:3.0, Date 30 Nov 2012 1 
Protocol 
Keratinocyte growth factor in Acute lung 
injury to REduce pulmonary dysfunction 
– a randomised placebo controlled trial
(KARE) 
Acronym: KARE 
Protocol Number: 10089DMCA-CS 
Version Number / Date:  3.0 30 Nov 2012 
EudraCT Number: 2010-021186-70 
REC Reference Number: 10/NIR02/32 
ISRCTN Number: ISRCTN95690673 
Health and Social Care R&D 
Office Reference Number: 
EAT/4210/09 
List of Amendments to Date: 1 amendment Protocol 2 to Protocol 2.1 to include the 
ISRCTN number and new EudraCT number 
Chief Investigator: Prof Danny McAuley 
Professor / Consultant 
Centre for Infection and Immunity 
Queen‟s University, Belfast 
Microbiology Building 
Grosvenor Road 
Belfast, BT12 6BN 
Protocol No: 10089DMCA-CS, Version No:3.0, Date 30 Nov 2012 2 
PROTOCOL AUTHORISATION 
 
 
Full Protocol Title:  Keratinocyte growth factor in Acute lung injury to REduce 
pulmonary dysfunction – a randomised placebo controlled 
trial (KARE) 
 
 
Protocol Number:  10089DMCA-CS 
 
 
Version Number / Date:  3.0 / 30 Nov 2012 
    2.1 / 08 Oct 2010 
 
 
A review of the protocol has been completed and is understood and approved by the  
following: 
 
 
 
 
Danny McAuley       30 Nov 2012 
Chief Investigator   Chief Investigator Signature  Date dd/mm/yyyy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol No: 10089DMCA-CS, Version No:3.0, Date 30 Nov 2012 3 
 
 
 
TRIAL TEAM 
 
Chief Investigator: Professor Danny McAuley 
 
Co-Investigators: Dr L J Mark Cross 
 
 Dr Cecilia O‟Kane 
 
 Professor Stuart Elborn 
 
 Professor Michael Matthay 
 
Clinical Trials Unit (CTU): Clinical Research Support Centre 
 
Education & Research Centre, The Royal Hospitals 
Grosvenor Road, Belfast, N. Ireland, BT12 6BA 
 
Trial Statistician: Mike Stevenson, Senior Biostatistician 
Clinical Research Support Centre 
Trial Data Manager: Data Manager, Clinical 
Research Support Centre. 
 
Study Sponsor: Professor Ian Young, Associate Medical Director for 
Research, Belfast Health and Social Care Trust,  
Royal Hospitals, Grosvenor Road, Belfast,  
BT12 6BA. 
 
  
 
Protocol No: 10089DMCA-CS, Version No:3.0, Date 30 Nov 2012 4 
Background Information 
Acute lung injury (ALI) is a common devastating clinical syndrome characterised by life-
threatening respiratory failure requiring mechanical ventilation and multiple organ failure 
and are a major cause of morbidity and mortality. ALI occurs in response to a variety of 
insults, such as trauma and severe sepsis. It affects all age groups; has a high mortality 
of up to 30-50% (Brun-Buisson, Minelli et al. 2004; Rubenfeld, Caldwell et al. 2005)  and 
causes a long-term reduction in quality of life for survivors (Dowdy, Eid et al. 2006). ALI 
has significant resource implications, prolonging intensive care unit (ICU) and hospital 
stay, and requiring rehabilitation in the community (Rossi, Simini et al. 2006). The cost 
per ICU bed-day exceeds £1800 and delivery of critical care to patients with ALI accounts 
for a significant proportion of ICU capacity. Based on available data, in the UK and 
Ireland it is estimated that up to 45000 cases of ALI occur, with an estimated 13000-
22000 deaths per year in patients with ALI (Brun-Buisson, Minelli et al. 2004; Rubenfeld, 
Caldwell et al. 2005; 2008). Only 54% of survivors are able to return to work 12 months 
after hospital discharge (Cheung, Tansey et al. 2006). The high incidence, mortality, 
long-term consequences and high economic costs mean that ALI is an extremely 
important problem. 
 
Mechanisms of ALI 
The pathogenesis of ALI involves pulmonary recruitment of macrophages and 
neutrophils. These cells are in an activated state characterised by upregulated 
expression of cell surface adhesion molecules, excessive cytokine production (tumour 
necrosis factor alpha (TNFα), interleukin (IL)-1β, IL-6, IL-8 and IL-10) and extracellular 
release of biologically active cytotoxic proteases including neutrophil elastase (NE) and 
matrix metalloproteinases (MMPs) (Ware and Matthay 2000). The resulting injury to 
alveolar epithelium and endothelium, which can be detected biochemically, determines 
the severity of lung injury (Modelska, Pittet et al. 1999). The damage to the alveolar 
barrier is central to the development of non-cardiogenic pulmonary oedema resulting in 
acute respiratory failure with refractory hypoxia and the requirement for mechanical 
ventilation. We have also demonstrated that increased pulmonary oedema is associated 
with reduced survival in patients with ALI (Craig, Duffy et al. 2009). In ALI patients with a 
markedly elevated dead space fraction has been identified as an independent predictor 
of mortality [21]. A significant fraction of the elevation in pulmonary dead space fraction is 
probably explained by lung vascular injury mediated via this pro-inflammatory cascade. 
In experimental and clinical studies, we and others have shown resolution of pulmonary 
oedema and improved outcome in ALI is associated with improved alveolar epithelial 
function (Ware and Matthay 2001; McAuley, Frank et al. 2004; Perkins, McAuley et al. 
2006; Perkins, Gao et al. 2008), suggesting that a strategy to accelerate epithelial repair 
in ALI may be beneficial 
 
Evidence for Keratinocyte Growth Factor (KGF) as a novel therapy in ALI  
Keratinocyte Growth Factor (KGF) is a 28 kDa heparin-binding member of the fibroblast 
growth factor family (FGF-7). KGF specifically binds to the KGF receptor, which is a 
splice variant of the FGF receptor 2, which is expressed only in epit helial tissues. KGF 
acts as a paracrine mediator of proliferation, differentiation and upregulation of 
cytoprotective mechanisms in epithelial cells including alveolar type 2 cells, hepatocytes, 
gastrointestinal epithelial cells, transitional urothelial cells and keratinocytes. 
KGF is known to modulate several mechanisms recognised to be important in alveolar 
epithelial repair. KGF; 
1. promotes epithelial proliferation which is critical to the restoration of alveolar  
architecture.  
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2. promotes epithelial migration, differentiation and epithelial wound healing (William 
McKeown, Hyland et al. 2003; Spielberger, Stiff et al. 2004; Shannon, McKeown et  
al. 2006).  
3. increases surfactant protein production. 
4. downregulates pro-inflammatory cytokines and enhances endothelial cell  
resistance to injury and alters MMP release (Gillis, Savla et al. 1999). 
5. reduces alveolar capillary permeability, pulmonary oedema and improves survival  
in animal models of ALI (Ware and Matthay 2002).   
6. has anti-apoptotic effects via the Akt pathway (Ray P, Devaux Y et al. 2003) 
Recombinant human KGF (palifermin) is a 140 amino acid protein with a molecular 
weight of 16.3 kilodaltons (kDa) and differs from endogenous KGF in that the first 23 N-
terminal amino acid residues have been to deleted to improve protein stability. Palifermin 
is produced by recombinant DNA technology in Escherichia coli (Blijlevens and Sonis 
2007).  
Palifermin is already used to decrease the incidence, duration and severity of oral  
mucositis in patients with malignancies associated with chemo and/or radiotherapy 
(Blijlevens and Sonis 2007). The recommended dosage for palifermin is 
60 micrograms/kg/day administered as an intravenous bolus and is licensed for a 
duration of 6 days (British National Fomularly 2010). The efficacy of KGF for accelerating 
epithelial repair in a non-pulmonary location in patients with severe dermal epithelial 
injury enhances interest in its potential use to treat epithelial injury in ALI.  
Recently novel data in an ex vivo human model of LPS-induced lung injury found that 
treatment with KGF improved lung endothelial and epithelial barrier function and 
enhanced the rate of alveolar fluid clearance, hence reducing alveolar oedema (Lee, 
Fang et al. 2009). Preliminary data from a double-blind, placebo-controlled study 
investigating KGF in a model of acute lung inflammation induced by inhaled 
lipopolysaccharide (LPS) in healthy human volunteers found pre-treatment with KGF 
60 micrograms/kg/day for 3 days was associated with increased bronchoalveolar lavage 
fluid (BALF) surfactant protein-D (SP-D), a type 2 alveolar epithelial cell biomarker. 
Increased BALF SP-D has been associated with improved outcome in ALI. Interestingly 
this was also associated with an increase in BALF interleukin-6 (IL-6) (personal 
communication; D McAuley). Finally, we have recently reported the use of KGF as a 
salvage therapy resulting in unexpected survival in a patient with ALI in the setting of a 
paraquat overdose with a high predicted mortality (Browne G, Bhavsar M et al. 2010). 
Therefore the accumulation of evidence from the literature of in vitro, animal and human 
models as well as clinical studies support KGF as a potential therapy for patients with 
ALI. We postulate that KGF may improve alveolar epithelial/endothelial barrier  
dysfunction and therefore KGF may improve pulmonary dysfunction in ALI. 
 
Risks to patients from study drug 
Keratinocyte growth factor (palifermin) can cause recognized side effects, the most 
common of which is rash which resolves upon withdrawal of treatment.  
Palifermin (5 µg/kg to 250 µg/kg) has been administered intravenously in a range of 
phase 1 clinical trials to healthy volunteers with a wide age range. KGF was well 
tolerated and safely administered with no serious adverse events (SAE) in this dose 
range. All adverse events (AE) were transient and resolved without intervention and no 
subject discontinued because of an AE (Zia-Amirhosseini, Salfi et al. 2006). The AE 
profiling was graded as mild to moderate. Study treatment AEs that occurred with a 
frequency greater than 10% are shown below (Zia-Amirhosseini, Salfi et al. 2006). 
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In a randomized placebo controlled study (n=212) of palifermin in patients to prevent oral 
mucositis (106 randomized to palifermin and 106 to placebo), the documented side 
effects were rash, fever, taste disturbance, discoloration of tongue, itching, altered touch 
sensation and peri-anal discomfort. Most of the adverse events were consistent with the 
action of palifermin on the epithelium (e.g., rash, pruritus, erythema, paresthesia, mouth 
and tongue disorders, and taste alteration). All the side effects are transient and were 
mild to moderate in severity (occurring approximately three days after the third dose of 
palifermin and lasting approximately three days), and not a cause for the discontinuation 
of study drug (Spielberger, Stiff et al. 2004). Palifermin was associated with a transient 
and asymptomatic increase in serum amylase and lipase levels. No correlation between 
abdominal pain or other clinical symptoms and increases in amylase or lipase was 
observed (Zia-Amirhosseini, Salfi et al. 2006).  No cases of pancreatitis have been 
reported from the patients with haematological malignancies and fractionation of the 
increased amylase demonstrated that this was predominantly salivary amylase in origin 
(Summary of Product Characteristics for Kepivance 2011). The pharmacodynamic effect 
of palifermin has been demonstrated by studying the effect on Ki67 staining in human 
buccal mucosal epithelial cells demonstrating that KGF can cause epithelial proliferation 
with maximal effect at 72 hours (Zia-Amirhosseini, Salfi et al. 2006).   
In an open label study the effect of renal function (normal eGFR to requiring 
haemodialysis) on the pharmacokinetics of palifermin has been investigated and there 
was no requirement for dose adjustment in patients with renal dysfunction (Gillespie B, 
Zia-Amirhosseini P et al. 2006). 
The recommended licensed dosage for palifermin for oral mucositis is 
60 micrograms/kg/day for 6 days (British National Fomularly 2010). There is no evidence 
of accumulation of study drug over this time period. 
Treatment will be discontinued if a serious adverse event occurs. The mean 
half-life ranges from 4.5 - 6 hours (Zia-Amirhosseini, Salfi et al. 2006). Overall it has 
been proven to be a well tolerated drug. 
 
Rationale for the KGF dose and duration 
Data from preclinical models 
There are a variety of animal models using KGF between 5 to 10 mg/kg in which 
beneficial effects have been demonstrated (Mason CM, Guery BP et al. 1996; Sugahara 
K, Iyama K et al. 1998; Ware and Matthay 2002). 
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Data from human subjects 
Palifermin is indicated for the treatment of oral mucositis in patients with haematological 
malignancies receiving myeloablative radiochemotherapy . The recommended licensed 
dosage for palifermin is 60 micrograms/kg/day for 6 days (British National Fomularly 
2010). 
The dose and duration of treatment for this study are based on this normal therapeutic 
dose for treatment of oral mucositis.  Futhermore, as the median duration of mechanical 
ventilation in patients with ALI is 6 days (Rubenfeld, Caldwell et al. 2005) a 6 day 
duration of treatment is appropriate for the treatment of patients with ALI. 
Therefore the choice of dose and duration of palifermin to be used in this study has 
extensively been used previously in both healthy volunteers and patients, with only 
transient minimum AEs and is effective at augmenting epithelial repair.  
 
There are no effective pharmacological therapies for ALI 
The Cochrane systematic review of pharmacological treatments that included 22 studies 
of 14 different drugs concluded that “effective pharmacotherapy for ALI is extremely 
limited, with insufficient evidence to support any specific intervention” (Adhikari, Burns et 
al. 2004). 
The National Heart, Lung and Blood Institute Working Group considered the future 
research directions in ALI in 2002 and concluded that clinical trials underpinned by 
mechanistic investigations were essential to develop new therapies for ALI (Matthay, 
Zimmerman et al. 2003). 
 
Hypothesis 
The hypothesis is that treatment with palifermin will improve surrogate clinical 
outcomes in adult patients with ALI and is safe.  
 
Trial objective 
The objectives of the trials are  
1) To conduct a randomised, double-blind, placebo-controlled phase 2 trial of 
palifermin for the treatment of ALI and 
2) To study the biological mechanisms of palifermin on pulmonary and systemic 
neutrophil function and inflammation; alveolar epithelial and endothelial function 
protease:antiprotease balance and lung extracellular matrix degradation and 
turnover 
 
Trial design 
Prospective, randomised, double-blind, placebo-controlled phase 2 , clinical study of 
palifermin in patients with ALI. 
 
The trial is summarised in Figure 1. 
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Figure 1. Trial schematic diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Within 72 hours 
of onset of ALI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Daily screening in ICU 
Does the patient have a diagnosis of ALI? 
(Acute onset AND PaO2/FiO2 ratio ≤ 40kPa AND bilateral infiltrates on CXR 
AND no evidence of left atrial hypertension AND ventilated) 
Excluded 
Failure to fulfil inclusion and exclusion 
criteria 
Patients with ALI assessed 
for eligibility 
 
Randomised 
to KARE study 
N=60 
 
Palifermin 
N=30 
Placebo 
N=30 
Consent obtained from the 
Per LR or Prof LR 
 
Excluded 
Consent declined 
 
Data collection 
Pulmonary and non-pulmonary organ function 
ICU and hospital outcomes 
Safety 
Blood, BAL and urine samples 
 
When patient has regained 
capacity they will be asked for 
consent to continue follow-up 
Patients who refuse to 
continue will be withdrawn  
 
Protocol No: 10089DMCA-CS, Version No:3.0, Date 30 Nov 2012 9 
Trial site 
ICUs at the Belfast Health and Social Care Trust (BHSCT) and University Hospital of 
Southampton, NHS Foundation Trust. 
. 
   
Population 
Patients will be prospectively screened daily to see if they fulfil the eligibility criteria for 
recruitment to the study. All patients with ALI will be entered into a screening log. If the 
patient is not recruited the reason will be recorded. Routinely collected fully anonymised 
patient demographics will also be collected on these patients. This will allow comparison 
to identify that the study population is representative of the overall cohort of patients. The 
research group have an established and effective system in place to screen and identify 
patients with ALI. 
 
Patients will be eligible to participate in the study if they fulfil the following criteria:  
 
Inclusion criteria: 
ALI (Bernard, Artigas et al. 1994) as defined by acute onset of: 
a. hypoxic respiratory failure (PaO2/FiO2 ≤ 40 kPa)  
b. bilateral infiltrates on chest X-ray consistent with pulmonary oedema. 
 c. no clinical evidence of left atrial hypertension or if measured, a pulmonary  
  arterial occlusion pressure (PAOP) less than or equal to 18 mmHg. 
d. requirement for  positive pressure mechanical ventilation via an 
endotracheal tube or tracheostomy. 
 
All ALI criteria (a-d above) must occur within the same 24-hour period. The onset of ALI 
is when the last ALI criterion is met. Patients must be enrolled within 72 hours of ALI 
onset 
 
Exclusion criteria: 
1. Age < 18 years 
2. More than 72 hours from the onset of ALI 
3. Pregnancy 
4. Participation in a clinical trial of an investigational medicinal product within 30 
days 
5. Consent declined 
6. Current treatment with KGF 
7. Known hypersensitivity to palifermin or Escherichia coli derived proteins 
8. Previous adverse reaction to palifermin. 
9. History of active malignancy excluding haematological malignancies. 
10. Chronic liver disease with Child-Pugh score greater than 12. 
 
Patients with ALI for more than 72 hours are excluded to evaluate the effects of KGF 
early in the course of ALI when alveolar damage is implicated in the development of 
ALI.  Patients <18 years old are excluded because of limited clinical trial data with 
KGF in subjects younger than 18 years. 
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Trial Intervention 
Patients will be randomised to Palifermin 60 µg/kg or normal saline placebo daily as 
a bolus intravenous injection for up to 6 days.  Administration will not occur through 
an intravenous line that has been flushed with heparin. The intravenous line will be 
flushed with normal saline prior to and after study drug administration. The first dose 
of study drug will be administered within 4 hours of randomisation and subsequent 
doses will be at 10 am daily starting on the following calendar day.  
 
Study drug termination criteria 
Study drug will be continued until one of the following conditions is met, whichever 
comes first: 
 
1. 6 days after randomisation (maximum treatment period) 
2. 2 days following discontinuation of assisted ventilation 
 Unassisted breathing is defined as extubated with supplemental oxygen or 
room air; or open T-tube breathing; or tracheostomy mask breathing; or 
CPAP ≤5 cm H20 without pressure support. Patients receiving pressure 
support via non-invasive ventilation will be defined as receiving assisted 
ventilation. 
3. Study drug related adverse event (AE) 
4. Discharge from Critical Care environment 
5. Death 
6. Discontinuation of active medical treatment 
7. Patient or relative request for withdrawal of patient from the study 
8. Decision by the attending clinician that the study drug should be 
discontinued on safety grounds  
 
Outcome Measures 
As this is a phase 2 clinical study, several outcomes will be evaluated to determine 
whether treatment with palifermin shows efficacy for important surrogate clinical and 
biologic outcomes. 
 
Primary outcome measure 
The primary endpoint of this clinical study is to evaluate the efficacy of palifermin to 
improve oxygenation index (OI) at day 7 or the last available OI prior to patient 
discontinuation from the study. OI is a physiological index of the severity of ALI and 
measures both impaired oxygenation and the amount of mechanical ventilation 
delivered. We and others have shown OI is independently predictive of mortality in 
patients with ALI (Fort, Farmer et al. 1997; Seeley, McAuley et al. 2008). We have 
chosen day 7 as we expect this time interval will minimise the competing effects of 
death and extubation, while allowing a sufficient time interval for a biological effect to 
occur. 
OI is calculated as (mean airway pressure (cm H20) x FiO2 x 100) ÷ PaO2 (kPa). 
These simple measurements are easily and routinely collected as part of standard 
ventilator practice. 
 
Secondary Outcome measures 
1. Oxygenation index (OI) at days 3 and 14 
2. Physiological indices of acute lung injury, as measured by respiratory 
compliance (Crs), and P/F ratio at days 3, 7 and 14 
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3. Change in sequential organ failure assessment (SOFA) score from baseline to 
day 7 and 14 
4. Safety and tolerability as assessed by the occurrence of  AEs and Suspected 
Unexpected Serious Reactions (SUSARs). 
 
Although the duration of ventilation and ICU stay as well as ICU and hospital 
mortality and 28-day mortality will also be documented, these important clinical 
outcomes are not included as major outcome measures as the study is not 
adequately powered to assess these outcomes. 
 
The secondary objective of the study is to measure the biological effects of KGF on:  
1. Systemic and pulmonary neutrophil function 
2. Systemic and pulmonary inflammatory response 
3. Systemic and pulmonary epithelial and endothelial function  
4. Systemic and pulmonary protease and anti-protease balance 
5. Pulmonary extracellular matrix (ECM) degradation and turnover 
 
Trial procedures 
Informed consent procedure 
The study will be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki. The Principal Investigator is responsible for 
ensuring that informed consent for trial participation is given by each patient or a 
legal representative. An appropriately trained doctor or nurse may take consent. 
Appropriate signatures and dates must be obtained on the informed consent 
documentation prior to collection of trial data and administration of the trial drug. If no 
consent is given a patient cannot be randomised into the trial. 
The incapacitating nature of the condition precludes obtaining prospective informed 
consent from participants. In this situation informed consent will be sought from a 
Personal Legal Representative or Professional Legal representative. 
 
Personal Legal Representative consent 
Informed consent will be sought from the patient‟s „Personal Legal Representative‟ 
(PerLR) who may be a relative, partner or close friend. The PerLR will be informed 
about the trial by the responsible clinician or a member of the research team and 
provided with a copy of the Covering Statement for the PerLR with an attached 
Participant Information Sheet (PIS) and asked to give an opinion as to whether the 
patient would object to taking part in such medical research. If the PerLR decides 
that the patient would have no objection to participating in the trial they will be asked 
to sign two copies of the PerLR Consent Form which will then be countersigned by 
the person taking consent. The PerLR will retain one copy of the signed Consent 
Form. The second copy will be photocopied and the photocopy placed in the 
patients‟ medical records whilst the original will be retained in the Trial Site File. 
 
Professional Legal Representative consent 
If the patient is unable to give informed consent and no PerLR is available, a doctor 
who is not connected with the conduct of the trial may act as a Professional Legal 
Representative (ProfLR). The doctor will be informed about the trial by the 
responsible clinician or a member of the research team and given a copy of the PIS. 
If the doctor decides that the patient is suitable for entry into the trial they will be 
asked to sign two copies of the Professional Legal Representative Consent Form. 
The doctor will retain one copy of the signed Consent Form. The second copy will be 
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photocopied and the photocopy placed in the patient‟s medical records; the original 
will be retained in the Trial Site File. 
 
 
Retrospective patient consent 
Patients will be informed of their participation in the trial by the responsible clinician 
or a member of the research team once they regain capacity to understand the 
details of the trial. The responsible clinician or a member of the research team will 
discuss the study with the patient and the patient will be given a copy of the PIS to 
keep. The patient will be asked for consent to participate in the trial and to sign two 
copies of the Consent to Continue Form which will then be countersigned by the 
person taking consent. The patient will retain one copy of the signed Consent Form. 
The second copy will be photocopied and the photocopy placed in the patients‟ 
medical records whilst the original will be retained in the Trial Site File. 
Where consent to continue is not obtained, consent from the legal representative will 
remain valid. If the patient refuses consent, data collected about the patient will not 
be entered into the analysis. 
 
Withdrawal of consent 
Patients may withdraw or be withdrawn (by PerLR or ProfLR) from the trial at any 
time without prejudice. Data recorded up to the point of withdrawal will be included in 
the trial analysis. If a patient or PerLR requests termination of the trial drug during 
the treatment period, the drug will be stopped but the patient will continue to be 
followed-up as part of the trial. If a patient or a PerLR withdraws consent during trial 
treatment, the trial drug will be stopped but permission will be sought to access 
medical records for data related to the trial. If a patient or PerLR wishes to withdraw 
from the trial after completion of trial treatment, permission to access medical 
records for trial data will be sought. 
 
Similar consent mechanisms have been used successfully in other trials in similar 
populations (Harvey, Harrison et al. 2005). 
 
Patient registration and randomisation procedure 
After informed consent, the researcher will contact the clinical trials pharmacist who 
will allocate a unique Subject Number to the patient and randomise the subject in a 
1:1 ratio to the designated treatment group. Randomisation will be stratified by 
presence of severe sepsis requiring vasopressors.  The clinical trials pharmacist will 
dispense the trial drugs. The researcher will then contact the CTU and register the 
randomised patient. 
Study drug will be dispensed as per local Pharmacy guidelines. If the total 6 doses of 
study drug for each patient will be dispensed by pharmacy they will be stored in a 
secure temperature monitored fridge. This will only be accessed by trained senior 
nursing staff of the ICU. The study drug will be reconstituted and administered 
intravenously by an appropriately trained ICU clinical staff independent of the clinical 
trial according to local guidelines and therefore ensuring blinding for the clinical trial 
staff. The clinical staff who administers the study drug will not be involved in any of 
the study specific assessments. Any omission of study drug will be recorded in the 
Case Report Form (CRF) to monitor treatment compliance. 
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Drug accountability 
The clinical trials pharmacist will be responsible for maintaining records of the study 
drug dispensed to patients in ICU including dates, quantity, lot number and expiry 
date. Drug administration will be recorded on the patient‟s prescription chart. At the 
end of the treatment period any remaining unused drug will be returned to the 
hospital pharmacy.  Destruction of trial medication will be in accordance with 
Pharmacy Department SOPs and hospital waste management policy. A record of 
destruction will be maintained 
 
 
Standardised management 
All patients will receive standardised management  with regards to feeding, antibiotic 
policy, fluid management and weaning. Patients will be managed using a 
standardised ventilation protocol aiming for tidal volumes of 6 ml/kg ideal body 
weight. 
The influence of other treatments provided to critically ill patients will be minimised 
as the study will be undertaken in a single centre where standardised care is 
delivered based on evidence based local guidelines.  
 
Assessments 
For routinely collected clinical data the NHS record will be the source document and 
for study specific clinical measurements the CRF will be the source document.  
 
Day 1 (baseline) data 
The following will be recorded; 
Patient demographics 
 Date of birth, gender, height, weight and underlying aetiology of ALI will be 
documented at baseline. Concurrent medications will also be documented.  
The Acute Physiology And Chronic Health Evaluation score II (APACHE II) 
Simplified Acute Physiology Score II (SAPS II)  
Oxygenation index 
P/F ratio 
Respiratory compliance (Crs) 
Pulmonary dead space 
Sequential organ failure assessment (SOFA) score 
Haemodynamic variables 
 Pulse, blood pressure, inotrope use 
Ventilation parameters 
 Mode of ventilation, Positive End Expiratory Pressure (PEEP), plateau 
pressure, peak pressure, tidal volume, and arterial blood gas (ABG) 
measurements 
Renal replacement therapy (RRT) 
 The reason for being on RRT will also be documented.  
Clinical laboratory assessments: renal and liver function, haematological parameters, 
coagulation parameters, C reactive protein and amylase 
Study drug administration 
 
Blood, BAL and urine will be taken at baseline prior to study drug administration (day 1) from 
all patients.  
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Sampling procedures are outlined below. 
 
 
 
 
Daily data 
All daily measurements will be recorded and collected between 10am and 12midday. 
 
Oxygenation index 
P/F ratio 
Respiratory compliance (Crs) 
Pulmonary dead space 
Sequential organ failure assessment (SOFA) score 
Haemodynamic variables 
Ventilation parameters 
Need for renal replacement therapy (RRT)  
Clinical laboratory assessments: renal and liver function, haematological parameters, 
coagulation parameters, C reactive protein and amylase 
Diuretic use 
Overall fluid balance including blood product transfusions, FFP, red cell, platelets  
ICU acquired infection 
 The incidence of ICU acquired infection will be recorded according to 
standardised definitions. 
Study drug administration 
Adverse event assessment 
 
The duration of ventilation and ICU stay as well as ICU and hospital mortality will 
also be recorded. 28-day mortality will also be documented. 
   
Day 4, 7 and 14 
BAL will be taken on day 4 
 
Blood, and urine will be taken on day 4 and 7, 14 
 
Sampling procedures 
Blood and urine sampling 
Twenty-five ml of blood will be collected by trained study staff and processed 
according to standard procedures as previously described (Shyamsundar, McKeown 
et al. 2009). 
In addition 10ml aliquots of urine will be collected by trained study staff.  
Bronchoscopy and BAL 
Bronchosopy and BAL will be undertaken and BAL fluid processed as previously 
described (Haslam and Baughman 1999; Shyamsundar, McKeown et al. 2009).  
In keeping with standard recommendations, patients who are receiving more than 
80% inspired oxygen or have a high positive end expiratory pressure (PEEP) of 
>15cm H2O will not undergo bronchoscopy and BAL. In addition if the ICU 
consultant has any concerns regarding safety the procedure will not be undertaken.  
Participants will be closely monitored during and after bronchoscopy and BAL. 
Participants will receive sedation and analgesia (to prevent discomfort) as part of 
standard care. Bronchoscopy and BAL can be associated with transient oxygen 
desaturation. Patients will be pre-oxygenated. Predefined stopping criteria are 
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established and If oxygen saturation, as measured by pulse oximetry falls to <93% 
bronchoscopy and BAL will be stopped.  
 
Samples will be labelled with the patient‟s unique Subject Number. 
All samples will be stored at –70oC until analysis. 
 
Samples will be stored beyond study completion. As new scientific data become available we 
will be able to use this resource of stored samples to investigate if this new data is relevant to 
ALI pending additional ethical approval.  
 
Laboratory measurements 
The following will be measured 
Systemic and pulmonary neutrophil function including measurement of total and 
differential white cell count, MPO and neutrophil apoptosis 
Systemic and pulmonary inflammatory response including measurement of CRP, 
cytokines (including TNFα, IL-1ra, IL-1β, IL-4, IL-6, IL-8, IL-10 and MCP-1), HO-1, 
adhesion and activation molecule expression, coagulation factors (including 
thrombin-anti-thrombin complex, tissue factor, protein C, thrombomodulin and 
plasminogen activator inhibitor-1) and RAGE ligands. In addition alveolar leukocytes 
cell lysates will be analysed for total and phosphorylated p38, ERK and JNK MAPKs, 
and STAT-1/-3 by western blot (Elkington, Emerson et al. 2005). Alveolar leukocytes 
cytoplasmic extracts will be probed by western blot for activated and total IκBα and 
β. Nuclear extracts will be analysed by NFκB and AP-1 transcription factor assays 
(Wickremasinghe, Thomas et al. 2004). 
Systemic and pulmonary epithelial and endothelial function including measurement 
of cell specific biomarkers (such as RAGE, SP-D, Ang I/II and vWF), measurement 
of alveolar permeability assessed by measurement of plasma and BALF total 
protein, albumin and immunoglobulin and in-vitro wound repair assessment in 
response to BAL fluid from subjects treated with or without palifermin (Geiser, 
Jarreau et al. 2000). Systemic endothelial function will also be measured by spot 
urine albumin:creatinine ratio (ACR). 
Systemic and pulmonary protease and anti-protease balance including measurement 
of MMPs (MMP-1,-2,-3,-7,-8,-9,-12,-13), serine proteases and anti-proteases. 
Pulmonary extracellular matrix (ECM) degradation and turnover as measured by 
urinary desmosine indexed to urine creatinine and procollagen peptide III. 
 
Alveolar leucocytes will be isolated to study their function, including inflammatory 
mediator release alone and in co-culture experiments as well as response to anti-
inflammatory agents in vitro. mRNA will be extracted and analysed for proteases and 
proteins modulating the inflammatory response. 
BAL fluid will also be used to study the influence of KGF treatment upon 
inflammatory mediator release, interstitial matrix turnover and apoptosis of alveolar 
epithelial cells alone and in co-culture experiments with endothelial cells and 
fibroblasts.  BAL fluid will also be investigated at baseline and on day 4 for both 
bacterial culture and for the presence of viruses.   A sample of BAL will also be sent 
for microbiological analysis to include assessment for anaerobic bacteria.  
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A summary of trial procedures is shown in Table 1. 
 
Table 1. Trial Procedures 
 Day 1 Day 2-3 Day 4 Day 5-6 Day 7 Day 8-13 Day 14 
Eligibility 
assessment  
X       
Informed 
consent 
X       
Randomisation 
 
X       
Baseline data 
 
X       
Daily data 
 
 X X X X X X 
Study drug 
administration 
X X X X    
Adverse events 
 
X X X X X X X 
BAL sampling X  X     
Blood and urine 
sampling 
X  X  X  X 
 
Data Management 
 
Data collection and recording 
All data for an individual patient will be collected by the Chief Investigator or their 
delegated nominees and recorded in the CRF.  
Patient identification in the CRF will be through their unique Subject Number allocated at the 
time of randomisation and initials. Data will be collected from the time the patient is 
considered for entry into the trial through to their discharge from hospital. 
Submitted data will be reviewed for completeness and entered onto a secure, backed-up 
custom database. Due care will be taken to ensure data safety and integrity, and compliance 
with the Data Protection Act 1998. 
 
Training Issues 
To ensure accurate, complete and reliable data, the CTU will do the following: 
 
• Be available for consultation with the trial personnel by mail, telephone and/or fax. 
• Review and evaluate CRF data, detect errors in data collection and request data 
verification. 
 
Data Storage 
All essential documentation and trial records will be stored by the Chief Investigator in 
conformance with the applicable regulatory requirements and access to stored information 
will be restricted to authorised personnel.  
 
Archiving 
Trial documentation and data will be archived for at least 15 years after completion of the trial 
in keeping with the applicable regulatory requirements. 
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Pharmacovigilance  
Definition of Adverse Events 
The EU Clinical Trials Directive 2001/20 provides the definitions given in Table 2. 
 
Table 2. Terms and Definitions for Adverse Events 
Term  Definition  
Adverse Event  
(AE)  
Any untoward medical occurrence in a participant to 
whom a medicinal product has been administered 
including occurrences which are not necessarily 
caused by or related to that product.  
Adverse Reaction  
(AR)  
Any untoward and unintended response in a 
participant to an investigational medicinal product, 
which is related to any dose administered to that 
participant.  
Unexpected Adverse 
Reaction  
(UAR)  
An adverse reaction the nature and severity of 
which is not consistent with the information about 
the medicinal product in question set out in the 
Summary of Product Characteristics (SPC) for that 
product (for products with a marketing 
authorisation)  
Serious Adverse Event 
(SAE)  
Serious Adverse 
Reaction (SAR)  
Suspected Unexpected 
Serious Adverse 
Reaction (SUSAR)  
Respectively, any adverse event, adverse reaction 
or unexpected adverse reaction that:  
 results in death  
 is life-threatening  
 requires hospitalisation or prolongation of 
existing hospitalisation*  
 results in persistent or significant disability or 
incapacity  
 consists of a congenital anomaly or birth 
defect  
is any other important medical event(s) that carries 
a real, not hypothetical, risk of one of the outcomes 
above and suspected transmission via a medicinal 
product of an infectious agent. 
 
 
Reporting Requirements 
Adverse Event (AE) Reporting 
The following AE will be recorded on the AE page in the CRF: 
• Moderate or severe rash requiring discontinuation of study drug.  In previous 
clinical studies with Palifermin there have been very infrequent 
discontinuations related to Palifermin induced dermatological reactions, but 
this will be monitored for in a daily basis to ensure volunteer safety.  
 Other AE requiring discontinuation of study drug 
 
These events will be included as part of the safety analysis for the trial and do not 
need to be reported separately to the CTU. 
 
Serious Adverse Events (SAEs) 
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SAEs that occur between trial entry and up to 28 days after completion of the study 
drug will be reported. 
All serious adverse events will be recorded in the adverse event report page in the 
CRF. The severity grade (mild, moderate, severe), duration (start and end dates) 
and relationship to the study drug will be recorded in keeping with regulatory 
requirements. 
The investigator must record any serious adverse events as defined above in the 
CRF, regardless of relationship to study drug as determined by the investigator. The 
investigator should attempt, if possible, to establish a diagnosis based on the 
subject‟s signs and symptoms. When a diagnosis for the reported signs or symptoms 
is known, the investigator should report the diagnosis as the adverse event, rather 
than reporting the individual symptoms.  
 
Suspected Unexpected Serious Adverse Reactions (SUSARs) 
Suspected Unexpected Serious Adverse Reactions (SUSARs) are SAEs that are 
unexpected i.e. their nature or severity is not consistent with the Summary of Product 
Characteristics and are considered to be caused by the study drug. 
These should be reported using the SAE form in the patient‟s CRF and must be 
reported by the Chief Investigator within 24 hours of becoming aware of them. To do 
this, the SAE form should be completed and faxed to the CTU. The Chief 
Investigator‟s assessment of causality of  SAEs (i.e. their relationship to trial 
treatment) will be reported on the SAE form. Subsequently, the Chief Investigator will 
be required to submit a full report on the resolution of the event. SUSARs will be 
recorded and reported in line with UK statutory requirements for clinical trials 
involving Investigational Medicinal Products (IMP) and copied to Swedish Orphan 
Biovitrum AB.  The Chief Investigator is responsible for reporting adverse events to 
the sponsor, Research Ethics Committee, MHRA and Swedish Orphan Biovitrum AB 
within required timelines.  
 
All adverse events should be treated appropriately. Treatment may include one or 
more of the following: no action taken (i.e., further observation only); non-drug 
therapy given; discontinuation of study drug; subject‟s hospitalization prolonged. The 
action taken to treat the adverse event will be recorded in the CRF. Once an adverse 
event is detected, it should be followed until its resolution or stabilized, or the events 
are otherwise explained and the outcome recorded in the CRF.  Adverse events are 
included in an annual report to the sponsor, Research Ethics Committee and MHRA. 
 
End of Trial 
The trial will end when 60 patients have been recruited and completed 28-day follow-
up. 
 
The trial will be stopped prematurely if: 
• Mandated by the Ethics Committee 
• Mandated by the MHRA 
• Mandated by the sponsor eg following recommendations from the DMEC 
• Funding for the trial ceases 
 
The Research Ethics Committee that originally gave a favourable opinion of the trial 
and the MHRA that issued the Clinical Trial Authorisation will be notified in writing if 
the trial has been concluded or terminated early.  
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Statistical considerations 
Sample Size 
The primary outcome measure will be the difference in OI between the palifermin 
and placebo treated groups at day 7. We have chosen day 7 as we expect this time 
interval will minimise the competing effects of death and extubation, while at the 
same time allowing a sufficient time interval for a biological effect to occur.  Based on 
our data from a recently completed clinical trial in ALI, the mean (standard deviation; 
SD) OI at day 7 in patients with ALI is 62 (51) cmH2O/kPa (Craig, Duffy et al in 
press.). A sample size of 56 subjects (28 in each group) will have 80% power at a 
two-tailed significance level of 0.05 to detect a clinical ly significant difference of 
39 cmH2O/kPa in OI between groups. In a previous phase 2 study of similar size, we 
have found that an intervention can demonstrate a change in OI of a similar 
magnitude (Craig, Duffy et al in press.) confirming a treatment effect of this size can 
be achieved. 
Although we anticipate few withdrawals or loss to follow-up we have allowed for this 
in the sample size calculation. In our previous single centre study of simvastatin in 
ALI there were no withdrawals. In a multi-centre UK study of pulmonary artery 
catheters in ICU patients (PAC-Man), no patients were lost to follow up, and only 
2.4% withdrew consent after recovering competency (Harvey, Harrison et al. 2005). 
Therefore a drop-out rate of 5% has been estimated and the study will require a total 
of 60 patients (30 in each group). 
Using the sample size of 60 patients determined from the primary outcome measure, 
the differences in the secondary outcomes at day 7 (Craig, Duffy et al in press.), that 
can be detected between the groups are presented in table 3. Data are mean (SD). 
All calculations assume 80% power at a two-tailed significance level of 0.05. 
 
Table 3. 
Outcome Value in patients 
with ALI 
Detectable 
effect size 
Crs (ml/cm H20) 57.8 (36.5) 27.8 
SOFA score 7.2 (4.2) 3.2 
 
Data Analysis 
Standard approaches will be used to detect patterns in missing data. Analyses will 
be on an intention-to-treat basis. A single analysis is planned at the end of the trial. A 
P value of 0.05 will be considered as significant.  
For continuously distributed outcomes, differences between groups will be tested 
using independent samples t-tests, analysis of variance (ANOVA) and analysis of 
covariance (ANCOVA) with transformations of variables to Normality if appropriate, 
or non-parametric equivalents. Chi-squared tests (or Fisher‟s Exact tests) will be 
used for categorical variables.  
Correlations between changes in the biological markers measured and physiological 
and clinical outcomes will assessed by appropriate graphical and statistical methods 
including Chi-square and Pearson‟s correlation coefficient. 
A detailed Statistical Analysis Plan will be written before the end of the trial.  
 
Regulations, ethics and governance 
The trial will comply with the principles, requirements and standards set out in the 
Research Governance Framework and The Medicines for Human Use (Clinical 
Trials) Regulations 2004 and subsequent amendments. 
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Sponsorship 
The BHSCT will act as sponsor. 
 
Regulatory approvals 
The trial will be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki. Approval from a Research Ethics Committee 
and a Clinical Trial Authorisation is needed before the start of the trial. 
The trial will registered with the International Standard Randomised Controlled Trial 
Number register. 
The trial will be registered with the Northern Ireland Clinical Research Network 
NICRN for Critical Care Clinical Research Portfolio. Accrual data on patient 
recruitment will be forwarded to the NICRN Co-ordinating Centre on a monthly basis 
from the CTU. 
 
Ethical considerations 
The vulnerability of this study group is fully appreciated and every effort will be 
undertaken to protect their safety and well-being. In line with The Medicines For 
Human Use (Clinical Trials) Regulations 2004 and subsequent amendments and to 
comply with the Research Governance Framework, consenting processes are 
standardised and a robust SOP for consenting participants will be adhered to. 
 
Patient Confidentiality 
Patient confidentiality will be maintained at every stage and compliance with the 
Data Protection Act (1998). 
 
Good Clinical Practice 
The trial will be carried out in accordance with the principles of the International 
Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines 
(www.ich.org). 
  
Trial Monitoring 
Site monitoring will be directed by the sponsor according to the study risk 
assessment.  Site visits will be performed on a regular basis to ensure that all 
regulatory requirements are met and to monitor the quality of the data collected. Site 
monitoring visits will involve source data verification where applicable. 
 
Indemnity 
The BHSCT will provide indemnity for any negligent harm caused to patients.  
 
Funding 
The study is funded by Health and Social Care R&D Office. Palifermin is provided as 
a gift by Swedish Orphan Biovitrum AB. 
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Safety and well being of study participants 
Participant safety and well-being are protected by implementation of the sponsors 
SOPs as set out in the Research Governance Framework and The Medicines for 
Human Use (Clinical Trials) Regulations 2004. As sponsor the BHSCT requires all 
research to be managed through a dedicated Research Management System. 
Systems are in place to ensure that all investigators are able to demonstrate that 
they are qualified by education, training or experience to fulfil their roles and those 
systems and procedures are in place which can assure the quality of every aspect of 
the trial. 
 
Safety of investigators 
The University and the Trust have Health and Safety Policies applicable to all 
employees. All personnel should also ensure they adhere to any other Health and 
Safety regulations relating to their area of work. The Chief investigator will ensure 
that all personnel have been trained appropriately to undertake their specific tasks.  
As the study fits closely to standard practice, there are few risks identified which are 
hazardous to the investigators. The study team will complete GCP and consent 
training prior to start up. 
 
Trial management 
The Clinical Research Support Centre (CRSC) CTU will be the Trial Co-ordinating 
Centre. 
 
Trial management group (TMG) 
The TMG will consist of the Chief Investigator, co-investigators and staff from the 
CTU. The Chief Investigator will have overall responsibility for the conduct of the 
study. Dr Mark Cross will be responsible on a day-to-day basis for the trial. Regular 
meetings of the TMG will be held to discuss and solve problems and monitor 
progress. The Chairman of CritPaL (Barry Williams) will advise the TMG and will 
represent the patient‟s perspective ensuring that the trial remains considerate of the 
needs of the patients and their families. 
The Chief Investigator will take responsibility for the need to change the protocol for 
any reason, reviewing relevant information from other sources and considering 
recommendations from the DMEC. 
 
Data Monitoring and Ethics Committee (DMEC) 
A DMEC will be appointed. The committee will be independent of the study team and 
will comprise an intensive care clinician and a clinician with experience in 
undertaking clinical trial. The DMEC will meet to agree conduct and remit. The 
DMEC will meet after the first 5 patients have been enrolled into the study and meet 
every 6 months thereafter. In the event of an occurrence of an unexpected severe 
adverse reaction an additional unplanned DMEC meeting will be convened. As this is 
a phase 2 trial, an interim analysis of efficacy is not planned although this issue can 
be discussed by the DMEC as required. The DMEC will function primarily as a check 
for safety, reviewing adverse events. They will report any issues pertaining to safety 
to the Chief Investigator. It will be the responsibility of the Chief Investigator to inform 
the sponsor who will take appropriate action to halt the trial if concerns exist about 
patient safety. 
 
Trial schedule  
Investigative site preparation: August 2010 
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Planned recruitment period: October 2010 – May 20113 
Planned completion of last patient: Mar 2013 
Biochemical analysis: Mar 2013 – May 2013 
Analysis and writing up of results: May 2013 – July 2013 
This timeline is based on our previous successfully completed phase 2 study in 
ALI (Craig, Duffy et al in press.). 
Dissemination 
The trial will be reported in accordance with the Consolidated Standards of Reporting 
Trials (CONSORT) guidelines (www.consort-statement.org). 
Dissemination will be achieved in several ways: (1) the findings will be presented at 
national and international meetings with open access abstracts on-line e.g. the 
American Thoracic Society annual meeting; and (2) in accordance with the open 
access policies proposed by the leading research funding bodies we aim to publish 
the findings in high quality peer-reviewed open access (via Pubmed) journals. This 
will secure a searchable compendium of these publications and make the results 
readily accessible to the public, health care professionals and scientists.  
Due to limited resources, it will be not be possible to provide each surviving patient 
with a personal copy of the results of the trial. However a lay person‟s summary of 
the principal findings of the results will be sent to all patients involved in the study at 
their request.  In addition a lay person‟s summary will be sent to local and national 
patient support and liaison groups (e.g. CritPaL). Where appropriate, research 
details will also be posted on institutional websites available to the general public. In 
addition, the most significant results will be communicated to the public through 
press releases. 
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Table S1. Mode of ventilation and adjunctive therapy 
Placebo Baseline ventilation Ventilation Day 7 Adjunctive Therapy 
SIMV Extubated None 
SIMV PS None 
SIMV PS None 
SIMV PS NMB 
PS Extubated None 
PS PS None 
PS BIPAP iNO and NMB 
SIMV PS NMB 
SIMV PS None 
PS Extubated None 
PS PS None 
SIMV Deceased None 
PS PS None 
PS Extubated None 
BIPAP PS NMB 
PS Extubated None 
SIMV PS None 
PS PS None 
SIMV SIMV NMB 
SIMV PS None 
PS Extubated None 
SIMV SIMV iNO and NMB 
PS Extubated Prone position and NMB 
PS Extubated None 
SIMV PS None 
SIMV Extubated None 
PS PS None 
SIMV PS None 
SIMV Extubated None 
SIMV PS None 
SIMV PS None 
KGF Baseline ventilation Ventilation Day 7 Adjunctive Therapy 
SIMV SIMV None 
SIMV PS None 
PS Deceased None 
SIMV PS None 
SIMV PS None 
SIMV SIMV None 
SIMV PS None 
SIMV Deceased None 
PS SIMV None 
PS PS None 
PS PS None 
SIMV Deceased None 
SIMV PS NMB 
BIPAP SIMV None 
SIMV PS None 
PS PS NMB 
SIMV SIMV NMB 
PS PS None 
SIMV PS None 
SIMV SIMV None 
SIMV PS NMB 
SIMV SIMV None 
SIMV SIMV NMB 
PS CPAP None 
PS PS NMB 
PS PS None 
SIMV PS None 
PS PS None 
SIMV Deceased iNO 
SIMV=Synchronized intermittent mandatory ventilation. PS= Pressure support ventilation. 
CPAP=Continuous positive airway pressure. NMB=Neuromuscular Blockade. iNO=inhaled nitric 
oxide. Prone=prone position. 
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Table S2. Mean airway pressure 
KGF Placebo Difference 
(95% CI) 
p-value 
Day 3 
Day 7 
Day 14  
10.8 ± 4.4 (n=26) 
10.0 ± 3.8 (n=23) 
11.2 ± 4.2 (n=11) 
10.3 ± 4.3 (n=30) 
10.0 ± 4.6 (n=21) 
9.0 ± 4.6 (n=5) 
0.54 (-1.80 to 2.89) 
0.00 (-2.58 to 2.58) 
2.18 (-2.78 to 7.14) 
0.65 
1.00 
0.36 
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Table S3. Classification of AEs. 
KGF Placebo 
Cardiac disorders 2  0  
Dermatology/Skin 0  1 
Gastrointestinal disorders 1 0 
General disorders (including multi-organ 
failure) 
5  4  
Hepatobiliary disorders 1 0 
Infections and infestations 2 0 
Nervous system disorders 2 0 
Respiratory - thoracic and mediastinal 
disorders 
1 0 
28 
Figure S1: Distribution histograms for OI and PaO2/FiO2 ratio at baseline and day 7. 
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Summary 
Background. Data from in vitro, animal and human lung injury models suggest 
that keratinocyte growth factor (KGF) may be beneficial in the acute respiratory 
distress syndrome (ARDS). The objective of this trial was to investigate the effect 
of KGF in patients with ARDS. 
Methods. This was a prospective, randomised, double-blind, allocation 
concealed placebo-controlled phase 2 trial conducted in two intensive care units, 
involving patients fulfilling the American-European Consensus Conference 
Definition of ARDS. Patients were randomised in a 1:1 ratio to receive either 
KGF (Palifermin 60 µg/kg) or placebo (0·9% sodium chloride solution) daily for a 
maximum of six days. Patients and investigators were blinded. The primary 
endpoint was oxygenation index (OI) at day 7. Secondary outcomes included 
respiratory compliance (Crs) and PaO2/FiO2 ratio, sequential organ failure 
assessment (SOFA) score and safety. Duration of ventilation, length of stay and 
mortality were recorded. The trial was registered with International Standard 
Randomised Controlled Trial Registry, number ISRCTN95690673. 
Findings. The trial recruited 60 patients with 29 patients receiving KGF and 31 
patients placebo. There was no significant difference between the two groups in 
OI at day 7 (the primary outcome) or in any other secondary physiological 
outcomes. The KGF group, compared to placebo, had fewer median ventilator-
free days (1 [0-17] versus 20 [13-22] days; difference -8 days, 95% CI -17- -2; P 
< 0·001), a longer median duration of ventilation in survivors (16 [13-30] versus 
11 [8-16] days; difference 6 days, 95% CI 2-14; P = 0·002) and a higher mortality 
at 28 days (31·0% versus 9·7%; risk ratio 3·2 95% CI 1·0-10·7; P = 0·054). 
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Interpretation. KGF did not improve physiological or clinical outcomes in ARDS 
and may be harmful. 
Funding. The Northern Ireland Public Health Agency Research and Development 
Division. 
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Research in context 
 
Evidence before this study 
We searched PubMed from January 1, 2000 to December 31, 2016 for non-animal, 
clinical studies with MeSH terms or synonyms for “acute respiratory distress 
syndrome”, and “Keratinocyte Growth Factor” in the title/abstract. Our search only 
identified one study in a model of lung injury induced by inhaled endotoxin in healthy 
human volunteers, which found KGF improved biomarkers of epithelial repair and 
resolution of injury. 
 
Added value of this study 
This randomised phase 2 clinical trial of KGF in patients with ARDS found no 
difference in the primary and secondary physiologic outcomes, however ventilator 
free days over 28 days were reduced and mortality was higher at 28 days in the KGF 
treated patients. 
 
Implications of all the available evidence 
KGF is not beneficial in the treatment of ARDS and may make clinical outcomes 
worse. KGF should not be used to treat patients who have ARDS. 
 
 
 
 
 
 
 
6 
 
Background 
The acute respiratory distress syndrome (ARDS) is a common clinical syndrome 
characterised by life-threatening respiratory failure requiring mechanical ventilation 
and multiple organ failure and is a major cause of morbidity and mortality.1,2 
The pathogenesis of ARDS involves pulmonary neutrophil- and macrophage-driven 
inflammation,3–5 and injury to the alveolar epithelium and endothelium.2 The 
resolution of pulmonary oedema and improved outcome in ARDS is associated with 
enhanced alveolar epithelial function, suggesting that a strategy to accelerate 
epithelial repair in ARDS may be beneficial.6 There is currently no effective 
pharmacological therapy which targets the underlying mechanisms implicated in the 
development of ARDS.7 The National Heart, Lung and Blood Institute Working Group 
considered the future research directions in ARDS and highlighted the lung 
epithelium as an important target for new therapies for ARDS.8 
Keratinocyte Growth Factor (KGF) modulates several mechanisms recognised to be 
important in alveolar epithelial repair9 and therefore may be a potential therapeutic 
intervention in ARDS. Recombinant human KGF (palifermin) is a 23 N-terminal amino 
acid truncated version of KGF. Palifermin is used for the treatment of oral mucositis in 
patients with malignancies associated with chemo and/or radiotherapy and has been 
shown to decrease the incidence, duration and severity of oral mucositis.10 This 
evidence of epithelial repair has led to interest in its potential use to treat epithelial 
injury in ARDS. Beneficial effects of KGF have been demonstrated in a variety of 
animal models of lung injury,11 in a human ex vivo lung perfusion model of endotoxin-
induced lung injury,12 and in a model of lung injury induced by inhaled endotoxin in 
healthy human volunteers.13 Therefore the available in vitro, animal and human 
model data, as well as clinical studies in mucositis, support KGF as a potential 
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therapy for patients with ARDS. The aim of the current trial was to test the hypothesis 
that KGF may augment epithelial repair and therefore improve pulmonary dysfunction 
in ARDS. 
 
Methods 
KARE was a randomised, double-blind, allocation concealed, placebo-controlled 
clinical trial undertaken in 2 adult general intensive care units (ICUs) both of 
which were based in a University Hospital setting in the United Kingdom.  
The trial was approved by a national research ethics committee (10/NIR02/32) 
and the MHRA (CTA number 32485/0021/001-0001 and EudraCT Number: 
2010-021186-70) and research governance departments at each site in the UK. 
The trial was registered on the International Standard Randomised Controlled 
Trial Registry (ISRCTN95690673). The trial was sponsored by the Belfast Health 
and Social Care Trust and was coordinated by the Northern Ireland Clinical Trials 
Unit (CTU). The trial design has been published in detail previously14 and the trial 
protocol is available in the online supplement. The trial is reported in line with the 
Consolidated Standards of Reporting Trials (CONSORT) guidelines.15 
Additional mechanistic outcomes are listed in the study protocol but are not 
reported in this paper. 
 
Patients 
Patients were eligible if they were intubated and mechanically ventilated and had a 
partial pressure of arterial oxygen to fractional inspired oxygen concentration 
(PaO2/FIO2) ratio of ≤ 40 kPa, if bilateral pulmonary infiltrates consistent with 
pulmonary oedema were present on chest radiograph, and if there was no evidence of 
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left atrial hypertension as defined by the American-European Consensus Conference 
Definition of acute lung injury/ARDS.16 
The exclusion criteria were presence of ARDS for more than 72 hours, current 
treatment with KGF, known hypersensitivity to palifermin or Escherichia coli derived 
proteins (palifermin is produced in an Escherichia coli based protein production system 
therefore hypersensitivity to Escherichia coli derived protein is an exclusion criteria), 
previous adverse reaction to palifermin, imminent withdrawal of medical treatment, 
chronic liver disease (Child-Pugh score greater than 12), history of active malignancy 
excluding haematological malignancies, age < 18 years, pregnancy, enrolment in 
another clinical trial of an investigational medicinal product within the previous 30 days 
and inability to obtain informed consent. The trial protocol was amended to permit 
enrolment of patients within a 72 hour window of the onset of ARDS from an original 
enrolment window of 48 hours, and also enrolment of patients with pancreatitis and 
haematological malignancies. Patients or their representatives provided written 
informed consent. 
 
Randomisation and masking 
Swedish Orphan Biovitrum AB supplied the palifermin for the trial. 
Patients were randomised in a 1:1 ratio to receive an IV bolus of either KGF 
(palifermin, 60 µg/kg) or placebo (0.9% sodium chloride solution) daily for a 
maximum of six days. The dose and duration of treatment for this study were 
based on the normal therapeutic dose for treatment of oral mucositis. The 
recommended licensed dosage for palifermin is 60 micrograms/kg/day for 6 
days.17 Futhermore, the median duration of mechanical ventilation in patients 
with ARDS was 5-6 days.18  
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The randomisation schedule was computer generated by the trial biostatistician. 
Randomization was by variable block size stratified by site and the presence of 
severe sepsis requiring vasopressors. An independent clinical trials pharmacist 
allocated the subject to the designated treatment group. Patients and 
investigators were blinded. 
Study drug was continued until 6 days after randomisation (maximum treatment 
period), 2 days following discontinuation of assisted ventilation, discharge from 
critical care, patient or relative request for withdrawal of patient from the trial, 
death or discontinuation of active medical treatment, study drug related serious 
adverse event (SAE) or decision by the attending physician that the study drug 
should be discontinued on safety grounds.  
At enrolment, the patients’ demographic characteristics, ventilatory and 
physiological variables and admission acute physiology and chronic health 
evaluation II (APACHE II) scores were recorded. The cause of ARDS was 
identified by the treating physician. For each day in the ICU, ventilatory and 
physiological variables were recorded. Daily ventilator parameters and 
corresponding arterial blood gas data were collected at a time point nearest to 
08:00 to 10:00, or nearest to this time point. Mean airway pressure was recorded 
in patients receiving pressure support ventilation. Plateau pressure was not 
recorded in patients receiving pressure support ventilation. Clinical care was at 
local physician discretion and based on the local ICU guidelines including low 
tidal-volume ventilation. 
Outcomes 
The primary outcome was oxygenation index (OI) at day 7. OI is a physiological 
index of the severity of ARDS which measures both impaired oxygenation and 
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the amount of mechanical ventilation delivered. OI has been found to be 
independently predictive of mortality in patients with ARDS.19 Secondary 
outcomes were OI at days 3 and 14, physiological indices of pulmonary function, 
as measured by respiratory compliance (Crs) and PaO2/FiO2 ratio at days 3, 7 
and 14, as well as a change in the sequential organ failure assessment (SOFA) 
score from baseline to day 3, 7 and 14. Pulmonary dead space fraction space 
was initially included as a secondary outcome but as this specialised 
measurement could not be undertaken at the second site the protocol was 
amended to remove this as an outcome. Safety and tolerability was assessed by 
the occurrence of adverse events (AEs). Although ventilator free days, the 
duration of ventilation and ICU stay as well as ICU and hospital mortality and 28-
day mortality were recorded, these clinical outcomes were not considered as 
outcome measures as the trial did not have power, as defined a priori in the 
study protocol, to assess these.  
It was intended that events that were expected in this population would not be 
reported as serious adverse events (SAEs), however the approved protocol 
stated all SAEs that occurred would be reported, regardless of the underlying 
relationship to the underlying clinical condition. Subsequently all SAEs were 
reported and relationship to underlying clinical condition recorded. 
 
Statistical Analysis 
Sample size assumptions were based on previously published data 20. Assuming 
a mean (standard deviation; SD) OI at day seven in patients with ARDS of 62 
(51) cmH2O/kPa,20 a sample size of 56 subjects (28 in each group) would need 
to be enrolled to have 80% power at a two-tailed significance level of 0.05 to 
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detect a mean reduction of 39 cmH2O/kPa in OI with KGF. The PAC-Man trial,21 
which recruited a similar critically ill population, had a dropout rate of 3% and 
therefore, a drop-out rate of 5% was estimated and the trial required a total of 60 
patients. 
Analyses were on an intention-to-treat basis. For OI, the primary analysis used 
the last available data prior to patient discontinuation from the trial if data was 
missing for a specified time point. In addition, the analysis for OI was repeated 
using only data available at the specified time point. Secondary outcomes were 
analysed using only data available at the specified time point. A single analysis 
was undertaken at the end of the trial with no interim analyses undertaken prior 
to the completion of the trial. A P value of 0.05 was considered as statistically 
significant and all tests were two-sided. For continuously distributed outcomes, 
differences between groups were tested using independent samples t-tests, 
analysis of variance (ANOVA) and analysis of covariance (ANCOVA) with 
transformations of variables to Normality if appropriate, or non-parametric 
equivalents. Chi-squared tests (or Fisher’s Exact tests) were used for categorical 
variables. Censorship of data collection occurred at day 90 post randomisation. 
 
Role of the funding source 
The funder or Swedish Orphan Biovitrum AB had no role in the trial design, trial 
conduct, data analysis, data interpretation, preparation of the manuscript or 
decision to submit the paper for publication. 
The corresponding author had full access to all the data of the study and had the 
final responsibility for the decision to submit for publication. 
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Results 
Patients were recruited from 23rd February 2011 until 26th February 2014. The 
trial completed when the planned 60 patients were recruited and 28-day follow-
up was completed. Of the 368 patients who were assessed for eligibility, 60 
(16%) underwent randomisation. All patients received their treatment as 
allocated and were analysed for the primary outcome (Figure 1).  
 
The baseline characteristics of the patients at randomisation were similar in the 
two study groups except higher Positive end-expiratory pressure (PEEP) and OI 
and a lower PaO2/FiO2 ratio in the placebo group. The main causes of ARDS 
were pneumonia, aspiration and sepsis (Table 1). Patients received study drug 
for a mean (±SD) of 5·1 ± 1·5 days in the KGF group and 5·5 ± 0·9 days in the 
placebo group (P = 0·21). The most common reasons for discontinuation of study 
drug were completion of the treatment course and death (Table 2). The modes of 
ventilation at baseline and day 7 and the adjunctive therapy received are given in 
Table e1. 
 
Outcomes 
The primary outcome was oxygenation index which was not different between 
the KGF and placebo groups at day 7 (62·3±57·8 versus 43·1±33·5, mean 
difference (95% CI) of 19·2 (-5·6 to 44·0); P = 0·13). OI was significantly lower in 
the placebo group at day 14 in the primary analysis (59·4±58·4 versus 
30·1±24·2, mean difference (95% CI) of 29·3 (5·6 to 53·0); P = 0·02), however 
when only data available at the pre-specified time point was analysed there was 
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no difference between the groups (Table 3). There was no difference in Crs, 
PaO2/FiO2 ratio or SOFA score between the groups up to day 14 (Table 3). 
There were significantly fewer ventilator-free days in the KGF compared to the 
placebo group (1 [0-17] versus 20 [13-22] days; median difference -8 days [95% 
CI -17- -2]; P < 0·001). Mortality in the KGF group was higher at 28 days. A total 
of 9 patients (31·0%) in the KGF group and 3 patients (9·7%) in the placebo 
group died by day 28 (risk ratio 3·2 [95% CI 1·0 – 10·7]; P = 0·054). Mortality in 
the KGF group was also higher at 90 days (44·8% versus 16·1%; risk ratio 2·8 
[95% CI 1·1 – 6·8]; P = 0·02). ICU and hospital mortality were also higher in the 
KGF group. Mortality was numerically greater in the KGF group at one year but 
did not reach statistical significance (P=0·06) (Table 4). 
 
For survivors only to day 90 (n=42), the duration of ventilation was increased in 
the KGF group (16 [13-30] versus 11 [8-16] days; P = 0·002). In addition, in the 
KGF group compared to the placebo group the duration of ICU stay (22 [14-34] 
versus 12 [10-19] days; P = 0·001) and hospital stay (Table 4) were also 
increased  
 
From randomization to day 90, the probability of survival (online supplement 
Figure e1a) or breathing without assistance (online supplement Figure e1b) was 
higher in the placebo group. 
 
The causes of death in the 9 patients who died by 28 days in the KGF group 
versus the 3 patients in the placebo group are listed in Table 5. Three of the 
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deaths by day 28 in the KGF group were related to central nervous system 
disorders including hydrocephalus, hypoxic brain injury and cerebral haematoma. 
 
Nineteen patients experienced adverse events (AEs) including 16 serious 
adverse events (SAEs). All of the serious adverse events were assessed by the 
chief investigator and an independent ICU physician as being due to the patient’s 
underlying medical condition and unrelated to study drug. Overall adverse events 
(AEs) related to study drug were significantly more common in the KGF group 
(Table 6). Both AEs assessed as related to the study drug were due to pyrexia. 
The classification of AEs is provided in the online supplement (Table e2).   
 
Discussion 
In this double-blind, randomised, placebo-controlled clinical trial in patients with 
ARDS, there was no difference in the primary physiologic outcome of 
oxygenation index. However, ventilator free days over 28 days were reduced and 
mortality at 28 days was higher in the KGF treated patients. These findings are in 
contrast to the pre-clinical and animal data as well as data from clinically relevant 
human models of ARDS11–13 which supported the potential for KGF as a therapy 
for ARDS. 
There are several issues which need to be considered in interpreting the results 
of this trial. First, the clinical outcomes of mortality and duration of ventilation 
were not pre-specified endpoints; therefore the findings of the adverse effect of 
KGF on clinical outcomes in this trial must be interpreted with caution. However, 
there was also no evidence to support a beneficial effect on physiological 
outcomes, including the primary outcome OI at day 7. At day 14, OI was lower in 
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the placebo group when the last available data point was carried forward if data 
were missing. This effect was lost when only available data were analyzed. A 
survivor bias in the placebo group may explain this discrepant finding. As shown 
in Table 5, three of the deaths in the KGF group were related to central nervous 
system disorders which are unlikely to be attributable to KGF. Finally, the 
placebo group had a lower than expected mortality in this trial (<10%). To put the 
unexpectedly low mortality in the placebo group in context, the mortality range 
from comparable single site and multi-centre studies as well as a large 
observational study in patients with ARDS was approximately 25-35%.1,20,22 
Therefore, the difference in mortality may relate, at least in part, to unexpectedly 
low mortality in the placebo group. The low mortality in the placebo group was 
unexpected in the setting of a randomised trial stratified for severe sepsis 
requiring vasopressors. At baseline patients in the placebo group had a higher 
PEEP and oxygenation index and a lower PaO2/FiO2 ratio but if anything this 
would indicate the placebo group may have been sicker at baseline and 
therefore unlikely to explain either the low placebo mortality or the differences in 
outcome. The trial was undertaken at only 2 sites which may limit the robustness 
of our findings, although a general population of critically ill adult patients was 
recruited. 
A potential limitation of the study is that the measurement of mean airway 
pressure while a patient is receiving pressure support ventilation may be less 
accurate due to the fact it includes the undetermined negative pleural pressure 
associated with the patient’s own respiratory effort. However regardless this does 
not modify the finding of worse clinical outcomes associated with KGF. 
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It is however possible that KGF caused harm. There are several potential 
reasons for this. It may be related to the dosage regimen used in this trial. In a 
nickel-induced murine model of lung injury, over-expression of KGF for 3 days 
prior to injury was protective while in contrast, KGF caused pulmonary 
inflammation and lung injury after 7 days or longer.23 Although the dosage 
regimen was chosen based on the treatment regimen to treat chemo-radiation 
induced mucositis,10 the interval between the doses of palifermin was shorter 
which may have been potentially harmful.24 We recruited a heterogenous cohort 
of patients with ARDS due to any aetiology in an attempt to ensure that our 
findings would be applicable to the overall population of patients with ARDS. 
However, it is possible that the response to KGF may be dependent on the 
aetiology of ARDS. In support of this concept, while in the majority of murine 
studies KGF is beneficial in experimental lung injury, in a murine model of lung 
injury induced by influenza A, KGF caused increased mortality associated with 
increased viral load and pulmonary inflammation.25 In our clinical trial no patients 
had a diagnosis of influenza, but it is possible that the specific aetiological factor 
driving ARDS predicts a different response to KGF. Differential effects of 
treatment may depend in part on the combination of biologic and clinical factors 
in ARDS, as shown in two retrospective studies using ARDSnet trial data.26,27 
Most of the previous pre-clinical studies used KGF as a preventive measure to 
mitigate the degree of lung injury.11,13 It is possible that KGF receptors may not 
be expressed on the target alveolar epithelial cells in patients in whom the 
epithelium is injured and therefore cannot mediate a therapeutic effect. 
Furthermore the effects of KGF on alveolar epithelial cell hyperplasia and 
proliferation may be different following injury than in the setting of pre-treatment 
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models. Another potential factor is the route of administration in this trial. Most of 
the animal studies utilised intra-tracheal instillation or inhalation of KGF11 which 
directly targets the injured lung epithelium allowing a lower dose to be used with 
less “off-target ” effects or systemic toxicity. We chose not to use local pulmonary 
delivery since in ARDS this not result in adequate KGF reaching oedema-filled or 
atelectatic regions of the injured lung. Given the targeted pulmonary delivery in 
many pre-clinical studies, systemic administration may have been effective. In a 
model of lung injury induced by inhaled endotoxin in healthy human volunteers, 
systemic administration of KGF at the dosage used in the current study was 
associated with evidence of alveolar epithelial repair and improved macrophage 
phagocytosis.13 While this healthy volunteers study informed the design of the 
current trial, in critically ill patients with ARDS with altered drug metabolism, 
systemic administration at this dose may not have been able to improve alveolar 
epithelial and macrophage function. 
Finally, there is a possibility that KGF is already maximally expressed in the 
setting of ARDS and additional exogenous KGF is not associated with any 
additional beneficial effects. 
In conclusion this trial found that KGF was not beneficial in terms of physiological 
outcomes in ARDS and may make clinical outcomes worse, and therefore it is 
recommended that KGF is not used to treat patients who have ARDS. 
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Figure 1: CONSORT diagram for screening, randomization and follow-up of the 
study participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Assessed for eligibility (n=368) 
Excluded (n=308) 
 Did not meeting eligibility 
criteria (n=213) 
 Declined consent (n=43) 
 Other reasons (n=52) 
29 were included in the analysis of 
the primary outcome 
No patients lost to follow-up 
29 were allocated to KGF 
 0 did not receive KGF 
No patients lost to follow-up 
31 were allocated to placebo 
0 did not receive placebo 
31 were included in the analysis of 
the primary outcome 
Randomised (n=60) 
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Table 1. Baseline demographic and clinical characterisitics 
 KGF Placebo 
Age – year 55.6±17.5 61.0±15.4 
Male sex – no. (%) 17 (58.6) 20 (64.5) 
Sepsis requiring Vasopressors — no. (%) 14 (48.3) 15 (48.4) 
Cause of ARDS† — no. (%)   
Smoke or toxin inhalation 1 (2.4) 0 (0) 
Aspiration  10 (24.3) 7 (14.6) 
Thoracic trauma  1 (2.4) 2 (4.2) 
Pneumonia  10 (24.3) 18 (37.5) 
Sepsis  11 (26.8) 16 (33.3) 
Pancreatitis  0 (0) 2 (4.2) 
Non-thoracic trauma  5 (12.2) 1 (2.1) 
Other 3 (7.3) 2 (4.2) 
APACHE II score 18.8±9.0 22.7±6.5 
LIS score 2.0±0.6 2.2±0.6 
Mean arterial pressure - mmHg 63.5±11.2 64.5±10.3 
Tidal Volume at randomisation - ml/kg PBW 7.9±2.6 8.3±2.1 
PEEP - cm H2O* 7.3±2.2 8.5±2.4 
Mean airway pressure - cm H2O 12.2±4.2 13.9±4.1 
Plateau pressure - cm H2O 23.3±4.7 24.0±3.3 
Oxygenation index - kPa* 72.3±51.6 103.2±60.2 
PaO2/FiO2 ratio - kPa* 21.4±8.6 15.8±5.7 
Compliance - ml/cm H2O 40.1±16.3 43.9±15.8 
SOFA score 9.5±4.0 8.9±3.1 
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*The baseline characteristics were similar in the study groups except for a higher 
PEEP (P=0.04), higher OI (P=0.04) and a lower PaO2/FiO2 ratio (P=0.006)  in the 
placebo group. 
† Patients may have had more than one cause of ARDS identified. 
# Other casuses of ARDS in the KGF group were blood transfusions, empyema 
and acute liver failure secondary to a possible drug reaction and in the placebo 
group were seizures due to possible encephalitis and pulmonary haemorrhage. 
Mean ± SD for continuous data and number (%) for categorical data. 
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Table 2. Treatment after trial entry 
 KGF Placebo 
Study drug given  
No. of days on treatment 
29 (100) 
5.2 ± 1.5 
31 (100) 
5.8 ± 0.6 
Reasons for termination of study drug 
6 days after randomisation 
2 days following discontinuation of assisted 
ventilation 
Study drug related AE 
Discharge from Critical Care 
Request from PerLR/ProfLR/patient 
Discontinuation of active treatment 
Decision by a physician on safety grounds 
Death 
Other 
 
22 (75.9) 
0 (0) 
 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
2 (6.9) 
4 (13.8) 
1 (3.4) 
 
26 (83.9) 
1 (3.2) 
 
0 (0) 
3 (9.7) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
1 (3.2) 
Protocol violations 0 0  
 
Mean ± SD for continuous data and number (%) for categorical data  
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Table 3. Outcome measures 
 
KGF 
 
Placebo 
 
Difference 
(95% CI) 
p-
value 
OI at day 7 or at the 
last available OI* 
62.3±57.8 (n=29) 
 
43.1±33.5 (n=31) 
 
19.2 (-5.6 - 44.0) 0.13 
OI at the last 
available OI* 
Day 3 
Day 14 
 
 
 
66.9±55.0 (n=29) 
59.4±58.4 (n=29) 
 
 
60.1±45.4 (n=31) 
30.1±24.2 (n=31) 
 
 
6.8 (-19.2 - 32.8) 
29.3 (5.6 - 53.0) 
 
 
0.60 
0.02 
OI# 
Day 3 
Day 7 
Day 14 
 
 
62.8±50.1 (n=26) 
45.4±32.1 (n=23) 
52.9±35.2 (n=11) 
 
60.9±45.9 (n=30) 
48.6±38.6 (n=21) 
43.3±37.2 (n=5) 
 
1.8 (-23.9 - 27.6) 
-3.2 (-24.8 - 18.3) 
9.6 (-31.8 - 51.0) 
 
0.89 
0.76 
0.63 
Respiratory 
compliance 
Day 3 
Day 7 
Day 14 
 
 
 
48.6±16.4 (n=16) 
51.1±25.2 (n=14) 
45.0±10.4 (n=6) 
 
 
53.5±28.8 (n=20) 
65.1±15.4 (n=7) 
77.5† (n=1) 
 
 
-4.8 (-21.3 - 11.6) 
-14.0 (-35.9 - 7.9) 
 
 
 
0.55 
0.20 
 
PaO2/FiO2 ratio# 
Day 3 
Day 7 
Day 14 
 
 
23.1±9.1 (n=26) 
27.6±10.4 (n=23) 
27.2±12.0 (n=11) 
 
20.3±6.0 (n=31) 
24.6±7.6 (n=21) 
21.3±9.0 (n=7) 
 
2.8 (-1.4 - 7.1) 
3.0 (-2.6 - 8.6) 
5.9 (-5.3 - 17.2) 
 
0.18 
0.29 
0.28 
SOFA score 
Day 3 
Day 7 
Day 14 
 
 
7.6 ± 3.6 (n=22) 
6.7 ± 3.0 (n=15) 
6.9 ± 2.0 (n=10) 
 
7.8±4.0 (n=29) 
7.9±4.1 (n=17) 
5.9±2.8 (n=7) 
 
-0.2 (-2.4 - 2.0) 
-1.1 (-3.8 - 1.5) 
1.0 (-1.4 - 3.5) 
 
0.83 
0.38 
0.39 
Change in SOFA 
score 
Day 3 
Day 7 
Day 14 
 
 
 
-1.4±1.9 (n=21) 
-2.9±2.7 (n=14) 
-2.3±1.7 (n=9) 
 
 
-1.2±2.3 (n=29) 
-2.0±3.0 (n=17) 
-3.9±3.8 (n=7) 
 
 
-0.3 (-1.5 - 1.0) 
-0.9 (-3.0 - 1.3) 
1.5 (-1.5 - 4.6) 
 
 
0.68 
0.42 
0.31 
 
Mean ± SD 
*Analysis used the last available data prior to patient discontinuation from the 
study if data was missing for a specified time point. Other outcomes were 
analysed using only data available at the specified time point. 
†No SD as n=1 
# Distribution histograms for OI and PaO2/FiO2 ratio have been provided in figure 
e2 in the online supplement.  
Mean airway pressure data (which was not a protocol specified outcome) is 
presented in Table e3.  
29 
 
Table 4. Clinical outcomes 
 
KGF 
n =  29 
Placebo 
n =  31 
Difference / Risk 
ratio* 
(95% CI) 
 
p value 
Ventilator free 
days to day 28 
1 (0-17) 
[0-22] 
20 (13-22) 
[0-25] 
-8 (-17- -2.0) <0.001 
Duration of 
ventilation (days)# 
16 (13-30) 
[11-90] 
11 (8-16) 
[4-50] 
6 (2-14) 0.002 
ICU stay (days)# 22 (14-32) 
[12-90] 
12 (10-19) 
[5-49] 
9 (3-17) 0.001 
Hospital length of 
stay (days)# 
39 (30-67) 
[22-90] 
23 (18-33) 
[12-84] 
17 (7-33) 0.001 
28 day mortality 9 (31.0) 3 (9.7) 3.2 (1.0-10.7) 0.054 
90 day mortality  13 (44.8) 5 (16.1) 2.8 (1.1, 6.8) 0.02 
ICU mortality 12 (41.4) 2 (6.5) 6.4 (1.6-26.2) 0.001 
Hospital mortality 14 (48.3) 4 (12.9) 3.7 (1.4-10.1) 0.003 
1 year mortality 15 (51.7) 8 (25.8) 2.0 (1.0-4.0) 0.06 
 
*Median (interquartile range); [range] and difference (95% CI) presented for 
continuous variables; number (%) and risk ratio (95% CI) for all categorical 
variables. #survivors only censored at day 90 (n=15 KGF, n=27 placebo). 
Fishers’s Exact test was used to compare categorical variables. 
 
 
 
 
 
 
  
30 
 
Table 5. Causes of death in patients who died by day 28. 
 
Treatment Group Cause of death 
KGF Multi-organ failure 
KGF Obstructive hydrocephalus and sepsis 
KGF Hypoxic brain injury 
KGF Sepsis and multi-organ failure 
KGF Sepsis and multi-organ failure 
KGF Cerebral haematoma 
KGF Myocardial infarction and ruptured aortic aneurysm and 
metastatic pancreatic cancer diagnosed during ICU 
admission 
KGF Systemic fungal infection 
KGF COPD and hypercapnic respiratory failure  
Placebo Ruptured aortic aneurysm with multi-organ failure 
Placebo Sepsis and multi-organ failure 
Placebo Multi-organ failure, pulmonary hemorrhage, pneumocystis 
pneumonia 
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Table 6. Safety outcomes 
 
 
 KGF Placebo OR 
(95% CI) p-value 
Total AEs – no. 14 5 4.9 (1.3 - 20.3) 0.008 
AEs related to study drug – 
no. 
2 0 -  
Total SAEs – no. 12 4 4.8 (1.2 - 23.0) 0.01 
SAEs related to study drug 
– no. 
0 0 - 
 
SAEs related to study drug 
and unexpected – no. 
0 0 - 
 
